mark
1.6K posts

mark
@mark03117754
added wLuna to the bag
Chino Hills, CA Katılım Mayıs 2021
671 Takip Edilen196 Takipçiler

@CryptoGeekNews Just stop with the hype we real investors are looking for a drop to 1$
English

🚨BREAKING: GOOGLE REPORTS THAT “THE FEDERAL RESERVE IS PREPARING TO ADOPT $XRP AS A GLOBAL PAYMENT SOLUTION.”
NOVEMBER 17TH IS SHAPING UP TO BE A HISTORIC DAY FOR THE XRP LEDGER.
MARK YOUR CALENDARS — THE REALFI ECOSYSTEM IS SET TO UNVEIL A MAJOR ANNOUNCEMENT FOR THE REAL TOKEN, BUILT ON XRPL AND POSITIONED TO TAP INTO A $650 TRILLION GLOBAL MARKET. 💰
JUST LOADED UP ON MORE XRP AND REAL! 💼
👉 BUY REAL TOKEN NOW:
xmagnetic.org/dex/REAL+rKVyX…
IF REAL TOKEN CAPTURES EVEN 1% OF THAT MARKET, ITS VALUE COULD EXPLODE FROM $0.03 TO OVER $65,400. 🚀 DYOR / NFA

English

ITS CONFIRMED!! $20 TRILLION APPROVED IN #XRP WILL CAUSE $317.80 PER XRP PRICE!! NOV 17TH WILL BEGIN!
NOV 17TH WILL BE IMPORTANT BCZ TRILLIONS MAY ENTER THE XRPL VIA REAL TOKEN WHICH MEAN ITS PRICE MAY GO FROM $0.03 TO $90-$80 INSTANTLY!! ‼️
RealFI@RealFITeam
Only 6 days Left. A major announcement is coming for the RealFI ecosystem, centered around the REAL Token (#XRPL). RealFi is here to stay. We’re solving a multi-trillion-dollar problem across payments, rewards, and real estate — all powered by the XRP Ledger and REAL Token technology. Stay tuned at PayRealFi.com — November 17th.
English

@TheMoneyApe not gonna lie… $WLFI sounds like it could explode
English

We successfully completed our strategic restructuring process, emerging as a financially stronger company. The growth mindset & entrepreneurial spirit that's always powered Wolfspeed will continue to drive us forward in this new era of energy. Learn more: wolfspeed.com/new-era/
English
mark retweetledi
mark retweetledi

Some Biotech Strategy:
I have been investing in biotech for over 20 years now. I have always been in the early stages of companies. My strategy has always been to buy a lot of promising companies and then add to the winners while dumping the losers. This allows me to maximize the gains on the long term winners and minimize the losses on the losers.
Biotech is a sector where 90% of the companies fail. If you are going to invest in speculative biotech, you have to have a strategy that minimizes those losers and maximize the winners. That or have super awesome luck where you buy one company, and it turns out to be the one that becomes a big winner. Luck is not at strategy though. You need to get used to being wrong a lot in biotech. That is the game. That is why I laugh when people criticize biotech investor for getting some of them wrong. I get a lot of biotech wrong. That is the nature of the game. Being a winner in biotech is all about strategy.
I have spent 20 years doing this by buying a group of companies and following the data. The data is what is important, but it's not the other winning factor. A good management will make the worst company a winner. The worst management will destroy even the best company. That is where many investors fail. They look at only the data and lose because management destroys value.
In 2015, I sold out of all my old winners like Celgene, Regeneron, Biomarin, and Alexion. That was just before the big biotech crash in late 2015 through 2016. That is when I started building my next batch of companies which did very well into the top of 2021. Many of them were up 500% to 800% at the peak when I sold. I went to 90% cash in 2021. My biggest regret was not going 100% cash lol.
Since then, I have been buying like crazy into the crash. The one mistake I made admittedly was buying too many early stage unproven companies that fail a lot more. Last year, I corrected that mistake because learning from mistakes it the key to being a great investor. I moved into my Super 8 late stage companies and started cutting the losers in the early stage companies as to reduce exposure. I called it "going back to basics". That is the strategy that served me well for 20 years.
The key things I want to teach any investor in biotech is that the space is very speculative. The statistics show that 90% of companies fail in early biotech. Vetting management teams and data is the key to success. Strategy is the only way to win as you need strategy to maximize winners and minimize loses. Don't be afraid to get some wrong. We all get a lot of them wrong. The strategy will keep you right.
English
mark retweetledi

@JessieChimni These two and $KYTX have had some of the worst losses from IPO. Cell therapies have been slow to research, fear is high because it's early and they haven't raised enough capital too see the trials through.
English
mark retweetledi

Based on my research, I opted to go with key names for my early stage Innovative 8 which will accompany my Super 8 late stage list. I went over them last night and chose the final list. I used a lot of criteria and here they are:
Innovative 8
1. $BEAM
2. $RXRX
3. $KYTX
4. $KYMR
5. $ABSI
6. $MGX
7. $PRME
8. $SDGR
I opted to remove $RLAY and $GPCR as I just didn't find them as innovative as the rest. I also left out $SANA and $IPSC from my early stage portfolio as they have been very disappointing thus far.
English


















